Organizational status of dialysis facilities and patient outcome: Does higher injectable medication use mediate increased mortality?

Health Services Research

Volumn 48, Issue 3, 2013, Pages 949-971

  Zhang, Yi ^a   Thamer, Mae ^a   Kshirsagar, Onkar ^a   Cotter, Dennis J ^a  

^a Medical Technology and Practice Patterns Institute Inc (MTPPI)   (United States)

Author keywords

chain; Dialysis facility; injectable drugs; mortality; profit status

Indexed keywords

IRON; RECOMBINANT ERYTHROPOIETIN; VITAMIN D;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DIALYSIS; DRUG USE; FEMALE; FOLLOW UP; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; MORTALITY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; UNITED STATES;

AGED; AMBULATORY CARE FACILITIES; COMORBIDITY; FEMALE; HEALTH BEHAVIOR; HEALTH SERVICES RESEARCH; HUMANS; INJECTIONS; KIDNEY FAILURE, CHRONIC; MALE; MEDICARE; MIDDLE AGED; OWNERSHIP; RENAL DIALYSIS; RETROSPECTIVE STUDIES; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 84877628962     PISSN: 00179124     EISSN: 14756773     Source Type: Journal    
DOI: 10.1111/1475-6773.12019     Document Type: Article

References (59)

1. Albitar, S., R. Genin, M. Fen-Chong, M. O. Serveaux, D. Schohn, and, C. Chuet,. 1997. " High-dose Alfacalcidol Improves Anaemia in Patients on Haemodialysis." Nephrology, Dialysis, Transplantation 12 (3): 514-8.
2. Austin, P. C., J. V. Tu, and, D. A. Alter,. 2003. " Comparing Hierarchical Modeling with Traditional Logistic Regression Analysis among Patients Hospitalized with Acute Myocardial Infarction: Should We Be Analyzing Cardiovascular Outcomes Data Differently? " American Heart Journal 145 (1): 27-35.
3. Baron, R. M., and, D. A. Kenny,. 1986. " The Moderator-Mediator Variable Distinction in Social Psychological Research: Conceptual, Strategic, and Statistical Considerations." Journal of Personality and Social Psychology 51 (6): 1173-82.
4. Brookhart, M. A., S. Schneeweiss, J. Avorn, B. D. Bradbury, J. Liu, and, W. C. Winkelmayer,. 2010. " Comparative Mortality Risk of Anemia Management Practices in Incident Hemodialysis Patients." Journal of the American Medical Association 303 (9): 857-64.
5. Christiansen, C. L., and, C. N. Morris,. 1997. " Improving the Statistical Approach to Health Care Provider Profiling." Annals of Internal Medicine 127 (8 Pt 2): 764-8.
6. Coyne, D. W., T. Kapoian, W. Suki, A. K. Singh, J. E. Moran, N. V. Dahl, A. R. Rizkala, and, D. S. Group,. 2007. " Ferric Gluconate Is Highly Efficacious in Anemic Hemodialysis Patients with High Serum Ferritin and Low Transferrin Saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study." Journal of the American Society of Nephrology 18 (3): 975-84.
7. D'Agostino, R. B., M. L. Lee, A. J. Belanger, L. A. Cupples, K. Anderson, and, W. B. Kannel,. 1990. " Relation of Pooled Logistic Regression to Time Dependent Cox Regression Analysis: The Framingham Heart Study." Statistics in Medicine 9 (12): 1501-15.
8. Department of Health and Human Services (DHHS), Office of Inspector General. 2004. Medicare Reimbursement for Existing End-Stage Renal Disease Drugs. OEI-03-04-00120. Washington, DC: DHHS, OIC.
9. Devereaux, P. J., H. J. Schunemann, N. Ravindran, M. Bhandari, A. X. Garg, P. T. Choi, B. J. Grant, T. Haines, C. Lacchetti, B. Weaver, J. N. Lavis, D. J. Cook, D. R. Haslam, T. Sullivan, and, G. H. Guyatt,. 2002. " Comparison of Mortality between Private for-Profit and Private Not-for-Profit Hemodialysis Centers: A Systematic Review and Meta-Analysis." Journal of the American Medical Association 288 (19): 2449-57.
10. DOPPS Practice Monitor (DPM). 2012. " Emerging Trends in Clinical Dialysis Care " [accessed on August 2010 to August 2011]. Available at http://www.dopps.org/DPM/DPM-highlights.pdf
11. Fan, Q., J. Liu, J. P. Ebben, and, A. J. Collins,. 2005. " Reuse-Associated Mortality in Incident Hemodialysis Patients in the United States, 2000 to 2001." American Journal of Kidney Diseases 46 (4): 661-8.
12. Feldman, H. I., M. Joffe, B. Robinson, J. Knauss, B. Cizman, W. Guo, E. Franklin-Becker, and, G. Faich,. 2004. " Administration of Parenteral Iron and Mortality among Hemodialysis Patients." Journal of the American Society of Nephrology 15 (6): 1623-32.
13. Fink, J. C., S. A. Blahut, A. E. Briglia, J. F. Gardner, and, P. D. Light,. 2001. " Effect of Center- versus Patient-Specific Factors on Variations in Dialysis Adequacy." Journal of the American Society of Nephrology 12 (1): 164-9.
14. Food and Drug Administration (FDA). 2012. " FDA Drug Safety Communication: Modified Dosing Recommendations to Improve the Safe Use of Erythropoiesis-Stimulating Agents (ESAs) in Chronic Kidney Disease " [accessed on November 8, 2012]. Available at http://www.fda.gov/drugs/ drugsafety/ucm259639.htm
15. Garg, P. P., K. D. Frick, M. Diener-West, and, N. R. Powe,. 1999. " Effect of the Ownership of Dialysis Facilities on Patients' Survival and Referral for Transplantation." New England Journal of Medicine 341 (22): 1653-60.
16. Government Accountability Office (GAO). 2006. " Report to the Chairman, Committee on Ways and Means, House of Representatives. End-Stage Renal Disease: Bundling Medicare's Payment for Drugs with Payments for All ESRD Services Would Promote Efficiency and Clinical Flexibility." GAO Publication No. GAO-07-77.
17. Government Accountability Office (GAO). 2007. " End-stage Renal Disease: Medicare Should Pay a Bundled Rate for All ESRD Items and Services." GAO Publication No. GAO-07-1050T.
18. Government Accountability Office (GAO). 2010. " CMS Should Monitor Access to and Quality of Dialysis Care Promptly after Implementation of New Bundled Payment System." GAO Publication No. GAO-10-295.
19. Hirth, R. A., 1997. " Competition between for-Profit and Nonprofit Health Care Providers: Can It Help Achieve Social Goals? " Medical Care Research and Review 54 (4): 414-38.
20. Hirth, R. A.,. 2007. " The Organization and Financing of Kidney Dialysis and Transplant Care in the United States of America." International Journal of Health Care Finance and Economics 7 (4): 301-18.
21. Hirth, R. A., M. N. Turenne, J. R. Wheeler, Y. Ma, and, J. M. Messana,. 2010. " Do Resource Utilization and Clinical Measures Still Vary across Dialysis Chains after Controlling for the Local Practices of Facilities and Physicians? " Medical Care 48 (8): 726-32.
22. Irvin, R. A., 2000. " Quality of Care Differences by Ownership in United States Renal Dialysis Facilities." ASAIO Journal 46 (6): 775-8.
23. Kalantar-Zadeh, K., R. Mehrotra, and, J. D. Kopple,. 2003. " Quality of Care in Profit vs Not-for-Profit Dialysis Centers." Journal of the American Medical Association 289 (23): 3089; author reply 89-90.
24. Kalantar-Zadeh, K., D. L. Regidor, C. J. McAllister, B. Michael, and, D. G. Warnock,. 2005. " Time-Dependent Associations between Iron and Mortality in Hemodialysis Patients." Journal of the American Society of Nephrology 16 (10): 3070-80.
25. Kanbay, M., M. A. Perazella, B. Kasapoglu, M. Koroglu, and, A. Covic,. 2010. " Erythropoiesis Stimulatory Agent- Resistant Anemia in Dialysis Patients: Review of Causes and Management." Blood Purification 29 (1): 1-12.
26. Leggat Jr, J. E., 2005. " Adherence with Dialysis: A Focus on Mortality Risk." Seminars in Dialysis 18 (2): 137-41.
27. Medicare Payment Advisory Commission (MedPAC). 2001. Report to the Congress: End-stage Renal Disease Payment Policies in Traditional Medicare, pp. 123-38. Washington, DC: MedPAC.
28. Medicare Payment Advisory Commission (MedPAC). 2003a. Report to the Congress: End-stage Renal Disease Payment Policies in Traditional Medicare, pp. 91-98. Washington, DC: MedPAC.
29. Medicare Payment Advisory Commission (MedPAC). 2003b. Report to the Congress: Medicare Payment Policy. Chapter 6: Quality of Dialysis Care and Providers' Costs. Washington, DC: MedPAC.
30. Mehrotra, R., and, J. D. Kopple,. 2001. " Nutritional Management of Maintenance Dialysis Patients: Why Aren't We Doing Better? " Annual Review of Nutrition 21: 343-79.
31. Messana, J. M., C. C. Chuang, M. Turenne, J. Wheeler, J. Turner, K. Sleeman, P. Tedeschi, and, R. Hirth,. 2009. " Association of Quarterly Average Achieved Hematocrit with Mortality in Dialysis Patients: A Time-Dependent Comorbidity-Adjusted Model." American Journal of Kidney Diseases 53 (3): 503-12.
32. Meyer, K. B., and, J. P. Kassirer,. 2002. " Squeezing More Cost and Care Out Of Dialysis: Our Patients Would Pay the Price." American Journal of Medicine 112 (3): 232-4.
33. Norton, E. C., and, D. O. Staiger,. 1994. " How Hospital Ownership Affects Access to Care for the Uninsured." RAND Journal of Economics 25 (1): 171-85.
34. Office of Inspector General. 2004. Medicare Reimbursement for Existing End-stage Renal Disease Drugs. Washington, DC: OIC Publication. Publication no. OEI-03-04-00120.
35. Palmer, S. C., D. O. McGregor, P. Macaskill, J. C. Craig, G. J. Elder, and, G. F. Strippoli,. 2007. " Meta-Analysis: Vitamin D Compounds in Chronic Kidney Disease." Annals of Internal Medicine 147 (12): 840-53.
36. Pfeffer, M. A., E. A. Burdmann, C. Y. Chen, M. E. Cooper, D. de Zeeuw, K. U. Eckardt, J. M. Feyzi, P. Ivanovich, R. Kewalramani, A. S. Levey, E. F. Lewis, J. B. McGill, J. J. McMurray, P. Parfrey, H. H. Parving, G. Remuzzi, A. K. Singh, S. D. Solomon, R. Toto, and, T. Investigators,. 2009. " A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease." New England Journal of Medicine 361 (21): 2019-32.
37. Port, F. K., and, G. Eknoyan,. 2004. " The Dialysis Outcomes and Practice Patterns Study (DOPPS) and the Kidney Disease Outcomes Quality Initiative (K/DOQI): A Cooperative Initiative to Improve Outcomes for Hemodialysis Patients Worldwide." American Journal of Kidney Diseases 44 (5 Suppl 2): 1-6.
38. Public Law. No.108-173, 623(a), 117 Stat. 2066:2315.
39. Rice, N., and, A. Leyland,. 1996. " Multilevel Models: Applications to Health Data." Journal of Health Services Research and Policy 1 (3): 154-64.
40. Robinson, B. M., and, F. K. Port,. 2009. " International Hemodialysis Patient Outcomes Comparisons Revisited: The Role of Practice Patterns and Other Factors." Journal of the American Society of Nephrology 4 (Suppl 1): S12-7.
41. Ronco, C., and, D. Marcelli,. 1999. " Options Regarding Outcome Differences in European and US Haemodialysis Patients." Nephrology, Dialysis, Transplantation 14: 2616-20.
42. Rozen-Zvi, B., A. Gafter-Gvili, M. Paul, L. Leibovici, O. Shpilberg, and, U. Gafter,. 2008. " Intravenous versus Oral Iron Supplementation for the Treatment of Anemia in CKD: Systematic Review and Meta-Analysis." American Journal of Kidney Diseases 52 (5): 897-906.
43. Singer, J. D., 1998. " Using SAS PROC MIXED to Fit Multilevel Models, Hierarchical Models, and Individual Growth Models." Journal of Educational and Behavioral Statistics 23 (4): 323-55.
44. Singh, A. K., L. Szczech, K. L. Tang, H. Barnhart, S. Sapp, M. Wolfson, D. Reddan, and, C. Investigators,. 2006. " Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease." New England Journal of Medicine 355 (20): 2085-98.
45. Sobel, M. E., 1982. " Asymptotic Confidence Intervals for Indirect Effects in Structural Equation Models." In Sociological Methodology 1982, edited by, S. Leinhardt, pp. 290-312. Washington, DC: American Sociological Association.
46. Steinbrook, R., 2006. " Haemoglobin Concentrations in Chronic Kidney Disease." Lancet 368 (9554): 2191-3.
47. Szczech, L. A., P. S. Klassen, B. Chua, S. S. Hedayati, M. Flanigan, W. M. McClellan, D. N. Reddan, R. A. Rettig, D. L. Frankenfield, and, W. F. Owen Jr,. 2006. " Associations between CMS's Clinical Performance Measures Project Benchmarks, Profit Structure, and Mortality in Dialysis Units." Kidney International 69 (11): 2094-100.
48. Szczech, L. A., H. X. Barnhart, S. Sapp, G. M. Felker, A. Hernandez, D. Reddan, R. M. Califf, J. K. Inrig, U. D. Patel, and, A. K. Singh,. 2010. " A Secondary Analysis of the CHOIR Trial Shows that Comorbid Conditions Differentially Affect Outcomes during Anemia Treatment." Kidney International 77 (3): 239-46.
49. Tangri, N., R. Moorthi, H. Tighiouhart, K. B. Meyer, and, D. C. Miskulin,. 2010. " Variation in Fistula Use across Dialysis Facilities: Is It Explained by Case-Mix? " Journal of the American Society of Nephrology 5 (2): 307-13.
50. Tentori, F., W. C. Hunt, C. A. Stidley, M. R. Rohrscheib, E. J. Bedrick, K. B. Meyer, H. K. Johnson, and, P. G. Zager, and I. Medical Directors of Dialysis Clinic. 2006. " Mortality Risk among Hemodialysis Patients Receiving Different Vitamin D Analogs." Kidney International 70 (10): 1858-65.
51. Tentori, F., J. M. Albert, E. W. Young, M. J. Blayney, B. M. Robinson, R. L. Pisoni, T. Akiba, R. N. Greenwood, N. Kimata, N. W. Levin, L. M. Piera, R. Saran, R. A. Wolfe, and, F. K. Port,. 2009. " The Survival Advantage for Haemodialysis Patients Taking Vitamin D Is Questioned: Findings from the Dialysis Outcomes and Practice Patterns Study." Nephrology, Dialysis, Transplantation 24 (3): 963-72.
52. Thamer, M., Y. Zhang, J. Kaufman, D. Cotter, F. Dong, and, M. A. Hernan,. 2007. " Dialysis Facility Ownership and Epoetin Dosing in Patients Receiving Hemodialysis." Journal of the American Medical Association 297 (15): 1667-74.
53. United States Renal Data System (USRDS). 2006. USRDS 2008 Annual Data Report: Atlas of End-stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.
54. United States Renal Data System (USRDS). 2007. USRDS 2008 Annual Data Report: Atlas of End-stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.
55. United States Renal Data System (USRDS). 2011. USRDS 2008 Annual Data Report: Atlas of End-stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.
56. Wish, J. B., 2006. " The Economic Realities of Erythropoiesis- Stimulating Agent Therapy in Kidney Disease." Kidney International 70: S21-5.
57. Zhang, Y., D. J. Cotter, and, M. Thamer,. 2011. " The Effect of Dialysis Chains on Mortality among Patients Receiving Hemodialysis." Health Services Research 46 (3): 747-67.
58. Zhang, Y., M. Thamer, K. Stefanik, J. Kaufman, and, D. J. Cotter,. 2004. " Epoetin Requirements Predict Mortality in Hemodialysis Patients." American Journal of Kidney Diseases 44 (5): 866-76.
59. Zhang, Y., M. Thamer, D. Cotter, J. Kaufman, and, M. A. Hernan,. 2009. " Estimated Effect of Epoetin Dosage on Survival among Elderly Hemodialysis Patients in the United States." Journal of the American Society of Nephrology 4 (3): 638-44.